Table 2.

(a and b) Number of samples (N = 98) presenting with antibodies against SARS-CoV-2 IgM (a) and IgG (b) (% positive) in relation to days from symptom debut. ELISA: enzyme linked immunosorbent assay, LFT: lateral flow test.

a
SARS CoV-2 IgM
Days since debut	No. of samples	Wantai ELISA	Livzon LFT	Acro LFT	CTK LFT	NEG in all LFT assays	NEG in all assays
1−7	3	3 (100)	1 (33)	3 (100)	2 (67)	–	–
8−14	23	20 (87)	20 (87)	18 (78)	19 (83)	1 (4)	1 (4)
15−21	32	32 (100)	30 (94)	26 (81)	29 (91)	1 (3)	–
22−28	12	12 (100)	11 (92)	11 (92)	12 (100)	–	–
>28	28	24 (86)	9 (32)	8 (29)	20 (71)	7 (25)	3 (11)

b
SARS CoV-2 IgG
Days since debut	No. of samples	Euroimmun ELISA	Livzon LFT	Acro LFT	CTK LFT	NEG in all LFT assays	NEG in all assays
1−7	3	0 (0)	1 (33)	2 (67)	1 (33)	1 (33)	1 (33)
8−14	23	13 (57)	17 (74)	21 (91)	18 (78)	2 (9)	2 (9)
15−21	32	28 (88)	30 (94)	32 (100)	30 (94)	–	–
22−28	12	11 (92)	12 (100)	12 (100)	11 (92)	–	–
>28	28	27 (96)	17 (61)	27 (96)	24 (86)	–	–